Study on the Effect of Povidone-Iodine, Hydrogen Peroxide, and Water for Injection on COVID-19, Influenza A, and RSV in Patients

3 1 1

What is this study about?

This clinical trial is focused on studying the effects of different oral antiseptics on certain respiratory viruses, specifically in patients diagnosed with COVID-19, influenza A, or respiratory syncytial virus (RSV). The trial will use antiseptics such as Betadine bucal, which contains the active ingredient povidone-iodine, and Agua oxigenada Foret, which contains hydrogen peroxide. These antiseptics are used as mouth rinses to see how effectively they can reduce the presence of these viruses in saliva.

The purpose of the study is to analyze the immediate effect of these antiseptics on the viral load in saliva and to determine how long this effect lasts, up to 7 hours after a single rinse. Participants will use the mouthwash, and samples of their saliva will be collected at different times to measure the amount of virus present. This will help researchers understand the potential of these antiseptics in reducing the spread of respiratory viruses.

The study will involve participants who have been diagnosed with one of the mentioned respiratory viruses and have shown symptoms for less than 5 days. The trial will not include those who are currently receiving antiviral treatments. The findings from this study could provide valuable insights into the use of oral antiseptics as a simple method to help control the spread of respiratory infections.

1 initial assessment

Upon joining the clinical trial, an initial assessment is conducted to confirm eligibility. This includes verifying a diagnosis of infection by respiratory viruses such as COVID-19, influenza A, or RSV. It is important that less than 5 days have passed since the appearance of symptoms and that no antiviral treatment is being received. Participants must be over 16 years old.

2 first mouthwash application

The first step in the trial involves using a mouthwash solution. The solution contains povidone, iodinated, hydrogen peroxide, and water for injection. The mouthwash is used by rinsing the mouth thoroughly, which is referred to as buccal use.

3 sample collection

After the mouthwash application, a saliva sample is collected. This sample is used to measure the viral load, which indicates the amount of virus present in the saliva.

4 monitoring period

The effect of the mouthwash is monitored for up to 7 hours. During this time, additional saliva samples may be collected to assess the duration of the mouthwash’s effect on reducing the viral load.

5 data analysis

The collected samples are analyzed to determine the D/T ratio, which helps quantify the proportion of intact viral particles. This analysis provides insight into the effectiveness of the mouthwash in reducing the presence of the virus.

Who Can Join the Study?

Have a diagnosis of infection by one of the following respiratory viruses: COVID-19, influenza A, or RSV (Respiratory Syncytial Virus).
Have had symptoms for less than 5 days. Symptoms are the signs of illness you can feel or see.
Not be receiving any type of antiviral treatment. Antiviral treatment is medicine used to treat viral infections.
Be over 16 years old.

Who Cannot Join the Study?

Patients who do not have a diagnosis of COVID-19, influenza A, or RSV (Respiratory Syncytial Virus) cannot participate.
Patients who are not within the specified age range for the study cannot participate.
Patients who are not able to provide informed consent cannot participate.
Patients with any condition that the study doctors believe would make it unsafe for them to participate cannot join the study.
Patients who are currently participating in another clinical trial cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Universidade De Santiago De Compostela	Santiago De Compostela	Spain

Trial status

Country	Status	Recruitment Start
Spain	Not yet recruiting	01.01.2025

Trial locations

Investigated drugs:

Oral Antiseptic 1 is a mouthwash used in this trial to help reduce the amount of viruses in the mouth. When you rinse your mouth with this antiseptic, it can kill or inactivate viruses like COVID-19, influenza A, and RSV. The goal is to see how well it works right after you use it and how long the effect lasts, up to 7 hours.

Oral Antiseptic 2 is another type of mouthwash being tested in the trial. Similar to the first antiseptic, it is designed to target and reduce viruses in your saliva. By using this rinse, the study aims to understand its immediate effect on viruses and how long it can keep the virus levels low in your mouth.

Oral Antiseptic 3 is also part of the trial and works like the other antiseptics. It is used to rinse the mouth and is tested for its ability to kill or reduce the presence of viruses in the saliva. The trial examines how quickly it acts against the viruses and the duration of its effectiveness over several hours.

Investigated diseases:

Viral infection

COVID-19 – COVID-19 is a respiratory illness caused by the coronavirus SARS-CoV-2. It primarily affects the respiratory system, leading to symptoms such as fever, cough, and difficulty breathing. The virus spreads through respiratory droplets and can lead to inflammation in the lungs. As the disease progresses, it may cause pneumonia and acute respiratory distress syndrome. In some cases, it can affect other organs, leading to a wide range of symptoms. The progression and severity of the disease can vary significantly among individuals.

Influenza A – Influenza A is a viral infection that affects the respiratory system, caused by the influenza A virus. It is characterized by symptoms such as fever, cough, sore throat, and muscle aches. The virus spreads through respiratory droplets and can lead to inflammation of the airways. As the infection progresses, it may cause complications like pneumonia, especially in vulnerable populations. The virus can undergo frequent genetic changes, leading to seasonal outbreaks. The severity of symptoms can vary, with some individuals experiencing mild illness and others more severe respiratory issues.

Respiratory Syncytial Virus (RSV) Infection – Respiratory Syncytial Virus (RSV) infection is a common respiratory virus that primarily affects the lungs and airways. It is most prevalent in infants and young children, causing symptoms such as runny nose, cough, and wheezing. The virus spreads through respiratory droplets and can lead to bronchiolitis or pneumonia. As the infection progresses, it may cause increased difficulty in breathing and decreased oxygen levels. RSV can also affect older adults and individuals with weakened immune systems. The severity of the infection can range from mild cold-like symptoms to more serious respiratory conditions.

Trial ID:

2024-515939-30-01

Protocol code:

OralAntiseptic_Virus

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Effect of Povidone-Iodine, Hydrogen Peroxide, and Water for Injection on COVID-19, Influenza A, and RSV in Patients

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?